Related references
Note: Only part of the references are listed.CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Y-T Tai et al.
LEUKEMIA (2014)
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
D. J. DeAngelo et al.
LEUKEMIA (2013)
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
D. Cirstea et al.
LEUKEMIA (2013)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy
M. Gupta et al.
LEUKEMIA (2012)
Bortezomib for AL amyloidosis: moving forward
Meletios A. Dimopoulos et al.
BLOOD (2011)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
Loredana Santo et al.
CLINICAL CANCER RESEARCH (2011)
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
A. Quintas-Cardama et al.
LEUKEMIA (2011)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2010)
Nonhistone protein acetylation as cancer therapy targets
Brahma N. Singh et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Chemical phylogenetics of histone deacetylases
James E. Bradner et al.
NATURE CHEMICAL BIOLOGY (2010)
HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A
Sumihito Togi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
David S. Schrump
CLINICAL CANCER RESEARCH (2009)
Acetylation and activation of STAT3 mediated by nuclear translocation of CD44
Jia-Lin Lee et al.
JOURNAL OF CELL BIOLOGY (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death
Changyou Li et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
Renate Burger et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis
Q-L Zhang et al.
LEUKEMIA (2009)
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3
Erik A. Nelson et al.
BLOOD (2008)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation (Publication with Expression of Concern. See vol. 24, pg. 4346, 2018)
Manisha Bhutani et al.
CLINICAL CANCER RESEARCH (2007)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BLOOD (2006)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
N Raje et al.
BLOOD (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Stat3 dimerization regulated by reversible acetylation of a single lysine residue
ZL Yuan et al.
SCIENCE (2005)
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma
T Hideshima et al.
ONCOGENE (2003)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
L Catley et al.
BLOOD (2003)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
N Mitsiades et al.
BLOOD (2003)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
Share Paper
